NYRx Formulary Update: Nucynta and Xtampza No Longer Covered
Click to Enlarge
Effective January 1, 2025, Collegium Pharmaceutical, the manufacturer of Nucynta®, Nucynta ER®, and Xtampza® is no longer participating in the Medicaid Drug Rebate Program and therefore these drugs will no longer be covered by NYRx. Prior authorization is not available for these drugs.
Prescribers should switch their patients to a preferred long-acting opioid product. Preferred LongActing Opioids include buprenorphine patch, fentanyl patch, and morphine sulfate ER tablet. Preferred drugs will not require PA if the required coverage parameters are found in the member’s Medicaid claim history at the time of pharmacy claim submission and if clinical criteria are met as outlined in the PDL. Non-preferred drugs will require PA.
